Loading…
Employees: 163
Size GC Corp. (005250.KS) is a South Korea Health Care company (Pharmaceuticals: Major) with a market value of $319M, the 446th largest of 495 South Korea companies the cockpit tracks. Shares closed at ₩9,470 on 6 Nov 2026.
Performance Over six months the shares fell 32.2%, against -24.6% for the median peer and -24.5% for the South Korea market (cap-weighted) — 6th lowest of 20 in its peer set.
Growth Revenue grew 9.6% over the last twelve months (peer median -4.4%); the operating margin is 1.2% (peer median 5.0%).
Valuation It trades at 1.2× enterprise value to sales against a peer median of 3.3× (3rd cheapest of 20).
Price implies For today's price to make sense, revenue must grow about 32% a year for seven years (Req g). Recent delivered growth is +7%, so the hurdle is +24 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 4.4 points below its cost of capital (5.0% WACC).
Next results Next results expected around 18 Nov 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₩2.49T | ₩2.45T | ₩2.20T | ₩2.06T | ₩2.08T |
| Revenue growth | — | +11% | +7% | -1% | — |
| Gross profit | ₩656B | ₩660B | ₩600B | ₩564B | ₩667B |
| EBITDA | ₩137B | ₩142B | ₩92.8B | ₩73.4B | ₩150B |
| Net income | -₩122B | -₩69.5B | ₩24.0B | -₩54.1B | ₩32.8B |
| Free cash flow | ₩37.1B | -₩86.6B | -₩134B | -₩130B | ₩23.9B |
| Capital expenditure | ₩164B | ₩150B | ₩57.7B | ₩133B | ₩127B |
| Total debt | ₩1.69T | ₩1.49T | ₩1.13T | ₩1.28T | ₩1.10T |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 005250.KS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -4.7% | -11.0% | 3rd highest of 20 |
| 6-month return | -32.2% | -24.6% | 6th lowest of 20 |
| Distance from 52-week high | -47.4% | -40.9% | 9th lowest of 20 |
| Revenue growth (TTM) | +9.6% | -4.4% | 5th highest of 19 |
| Operating margin | 1.2% | 5.0% | 9th lowest of 20 |
| EV / Sales | 1.2× | 3.3× | 3rd cheapest of 20 |
| Growth the price implies (Req g, 7 yrs) | 31.5% | 5.7% | 3rd most demanding of 14 |
| Growth delivered (Del g) | +7.4% | +0.5% | 3rd highest of 14 |
| Hurdle (Req g minus delivered) | +24.2 pp | +7.8 pp | 4th most demanding of 14 |
| ROIC minus cost of capital | -4.4 pp | -5.7 pp | 9th highest of 19 |
| EV / EBITDA | 21.1× | 8.0× | 2nd most expensive of 7 |
| Net debt / EBITDA | 11.6× | 0.8× | most indebted of 7 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| GC Corp. 005250.KS | South Korea | $319M | -32% | +10% | 1% | 1.2× | 31.5% | +7.4% |
| Eikon Therapeutics EIKN | United States | $320M | -41% | n/a | n/a | n/a | n/a | n/a |
| Enanta Pharmaceuticals ENTA | United States | $320M | -28% | +1% | -90% | 4.8× | n/a | n/a |
| Shandong Sito Bio-technology 300583.SZ | China | $318M | -26% | +19% | 6% | 2.5× | 2.7% | +2.3% |
| Zhejiang Shengda Bio-Pharm 603079.SS | China | $318M | -29% | -3% | 7% | 2.5× | 5.7% | -0.3% |
| Ind-Swift Laboratories INDSWFTLAB.NS | India | $321M | +149% | +66% | 9% | 3.5× | n/a | n/a |
| 6467 6467.TW | Taiwan | $322M | n/a | n/a | -2,618% | 1,229.5× | n/a | n/a |
| Hainan Huluwa Pharmaceutical 605199.SS | China | $322M | -21% | -32% | -58% | 5.0× | 2.5% | -4.9% |
| Kitazato 368A.T | Japan | $317M | -9% | +9% | 52% | 3.1× | -16.7% | +5.4% |
| Solara Active Pharma Sciences SOLARA.NS | India | $323M | +23% | +27% | 8% | 2.3× | 37.7% | -3.2% |
| Swedencare SECARE.ST | Sweden | $315M | -23% | +3% | 7% | 1.7× | 5.5% | +62.1% |
| Ocugen OCGN | United States | $314M | -39% | -11% | -1,444% | 66.5× | n/a | n/a |
| Enwei Pharmaceutical 301331.SZ | China | $326M | -20% | -7% | 5% | 2.3× | 15.1% | +7.3% |
| Zhejiang Zhenyuan Share 000705.SZ | China | $312M | -25% | -33% | -5% | 1.1× | n/a | n/a |
| Emergent BioSolutions EBS | United States | $312M | -27% | -18% | 5% | 1.0× | -0.1% | -13.7% |
| Hangzhou Tianmushan Pharmaceutical Enterprise 600671.SS | China | $327M | -10% | -19% | 5% | 11.5× | 22.5% | +0.5% |
| Beihai Gofar Chuanshan Biological 600538.SS | China | $328M | -38% | +10% | -8% | 6.2× | n/a | n/a |
| Standard Chemical & Pharmaceutical 1720.TW | Taiwan | $329M | 0% | +3% | 21% | 1.8× | -10.4% | +10.3% |
| Honz Pharmaceutical 300086.SZ | China | $330M | -35% | -23% | -54% | 7.9× | 58.0% | -12.8% |
| Shanxi C&Y Pharmaceutical 300254.SZ | China | $308M | -44% | -6% | 9% | 3.3× | 10.1% | +0.6% |
| Chengdu Huasun Technology 000790.SZ | China | $333M | -22% | -36% | -57% | 5.9× | 28.5% | -6.4% |